Case Report of Small Hepatocellular Carcinoma Complicated with an Isolated Portal Vein Tumor Thrombosis

Shi JY1, Wang XY1, Zhou J2, Fan J2 and Gao Q1*

1Institute of Liver Cancer, Fudan University, China
2Institute of Biomedical Sciences, Fudan University, China

Abstract

HCC has a high propensity to invade into the portal vein by direct venous extension or metastasis, which may cause tumor thrombosis that occurs in up to 70% of patients. It is well recognized that Portal Vein Tumor Thrombosis (PVTT) is a major detrimental prognosticator in HCC and almost all staging or prognostic systems for HCC include PVTT as an important parameter. Herein, we reported an interesting HCC case, that is, a male patient with a 30-mm mass in the right lobe and an isolated “mural” portal vein thrombosis in the right portal branch. The patient received hepatectomy and removal of the portal vein thrombosis. The pathological diagnosis proved that both the liver mass and the portal vein thrombosis were HCC. According to our medical records, it’s a rare case of small hepatocellular carcinoma with such severe PVTT.

Conclusion: It is vital to pay more attention on PVTT in HCC patients for evaluating the postoperative outcome and optimizing treatment strategies.

Keywords: Portal vein tumor thrombosis; Small hepatocellular carcinoma

Introduction

HCC is the second most common cause of cancer-related death worldwide and accounts for more than 600,000 new cases per year [1]. Only ~30% of patients with HCC are eligible for curative treatment involving liver transplantation and surgical resection [2]. Of note, HCC has a propensity to invade into the portal vein by direct venous extension or metastasis, which may cause tumor thrombosis that occurs in up to 70% of patients [3,4]. Portal Vein Tumor Thrombosis (PVTT) may lead to wide intrahepatic dissemination of the tumor, exacerbate portal hypertension, and reduce portal flow, resulting in upper gastrointestinal hemorrhage and deterioration of liver function. Previous studies have reported that the median survival of patients with PVTT was 2.7-4.0 months if left untreated, indicating that PVTT is a major detrimental prognosticator in HCC [3]. Almost all staging or prognostic systems, such as the TNM, Cancer of the Liver Italian Program (CLIP), Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH), Japan Integrated Staging (JIS) and Barcelona Clinic Liver Cancer (BCLC), include PVTT as an important parameter [5]. Moreover, patients with PVTT at different locations in the portal vein have different prognoses after liver resection, promoting the formulation of several specific PVTT microscopic or macroscopic classifications based on the extent of the tumor thrombus in the portal vein [6,7]. Here, we presented an interesting HCC case, that is, a male patient with a small mass in the right lobe and an isolated “mural” portal vein thrombosis in the right portal branch to underline the significance of PVTT in management of HCC.

Case Presentation

A 54-year-old man suspected with hepatocellular carcinoma (HCC) identified by surveillance with α-fetoprotein and ultrasound was admitted to our hospital. He has a history of hepatitis-B virus (HBV) positivity for over 20 years without any anti-HBV treatment; however, the development and exact duration of HBV-related cirrhosis in this patient was unclear. He denied familial history of HBV and HCC, nor any alcohol consumption. The serum α-fetoprotein was 8246.0 ng/mL (normal range: <20 ng/mL) and liver function test was normal. The patient’s Eastern Cooperative Oncology Group performance status was 0 and Child-Pugh classification was A. Contrast-enhanced computed tomography (CT) showed a 30-mm hepatic mass with an irregular margin at segment VII that...
appears as a hypo-attenuating lesion during venous phase (Figure 1A) with limited enhancement during arterial phase (not shown). In particular, an isolated portal vein thrombosis was observed in the right portal branch with slight enhancement (Figure 1B). The portal vein thrombosis displayed the pattern of a mural thrombosis, leaving the portal flow unaffected (Figure 1C). No definable extrahepatic metastases to the regional lymph node, lung, brain and bone were detected, as proved by multiple radiological examinations. The patient underwent segmentectomy of segment VII, removal of the portal vein thrombosis and dissection of hilar lymph nodes on Aug. 8, 2012. After the removal of the portal vein thrombosis, we performed a bloodletting with 400ml blood via portal vein to prevent tumor cells remaining. The pathology reported a moderately differentiated HCC (Edmondson grade II), with surrounding microscopic spreading nodules and a free resection margin (Figure 2A). Notably, the portal vein thrombosis was also proved to be HCC (Figure 2B and 2C). Immunohistochemical staining of the tumor showed GPC-3 (Figure 3A), HepPar-1 (Figure 3B) and CD34 (Figure 3C) positivity. The nontumor cirrhotic liver was graded as Scheuer system G2S4. No metastases were detected in the dissected lymph nodes. The patient recovered uneventfully and was discharged home on postoperative day 7. After three weeks of surgery, he got an ultrasound examination which showed a new thrombus in the right portal branch and then he received transhepatic arterial chemotherapy and embolization after one month of surgery with a mixture of 1g 5-FU, 150mg Oxaliplatin, 30mg Epirubicin and 10ml iodized oil. Unfortunately, he got severe malnutrition with ascites after discharge and died of dyscrasia on May 15, 2013.

Discussion

It is well known that the advent of PVTT is significantly associated with the presence of highly metastatic HCC nodule(s) or heavy tumor burden in the liver parenchyma. Only two previous publications have reported HCC presenting only as PVTT with no demonstrable tumor in the liver parenchyma outside the portal vein [8,9]. In HCC, while the hepatic artery is the feeding vessel, the portal vein serves mainly as an efferent vessel. As such, the main mechanism for the formation of PVTT is that tumor cells invade efferent vessels, engorge in the vascular cavity, and extend beyond the capsule to branches of the portal vein [4]. Hence, PVTT usually presents as a continuous architecture that starts microscopically from the HCC nodule, prorogate along portal branches and ends with occlusive thrombus formation. To our knowledge, this case represents the first established small HCC with isolated PVTT, in which the PVTT showed the pattern of mural thrombosis, leaving the portal flow unaffected. The exact mechanism for this distinct type of “partial or patent” PVTT remains largely unknown. A group of risk factors, including the location of the PVTT near the divaricator of portal trunk where turbulence of blood flow is likely to occur, portal hypertension due to liver cirrhosis, communication between hepatic artery and portal vein, and nourishing vessels alone the portal vein, may collaboratively have important roles.
The treatment of HCC with PVTT is complicated and controversial. Accumulated evidence has shown that certain therapeutic modalities, including surgery, radiotherapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and combined treatment can improve the survival of HCC patients with PVTT [10]. With improvement of surgical techniques, more and more patients with HCC and PVTT benefit from surgical intervention such as liver resection with PVTT removal. In Japan and western countries, only a small proportion of HCC patients with PVTT undergo hepatic resection. In China, more than 30% of patients are found to have advanced HCC with PVTT when the liver cancer is first diagnosed, among which about 10% receive liver resection [11]. We chose surgical resection and PVTT removal for this case, considering the fact that only single HCC nodule was detected in a liver with preserved function. In addition, before operation and pathological diagnosis, we cannot rule out the possibility that the isolated thrombosis in this case may be a benign one, although slight enhancement of the thrombus was seen during arterial and venous phase of CT scan.

In conclusion, the presence of "partial or patent" PVTT in untreated HCC patients, especially in those with a small tumor, is rare and not reported previously. It has been documented that tumor vascular invasion was observed in 48.4% of HCC tumors <2.0 cm, in 59.1% of those 2.1 to 3.0 cm, and in 73.3% of those 3.1 to 5.0 cm in diameter [4], suggesting the possibility of development of PVTT during very early stage of HCC. Consequently, it is vital to consider this factor in evaluating the postoperative outcome and in stratifying patients for adjuvant therapies, and to develop more effective treatment strategies for HCC with PVTT.

References